Current and emerging therapies for insomnia

Area of Science:

• Sleep Medicine
• Pharmacology

Background:

• Chronic insomnia affects up to 10% of US adults, with higher prevalence in women and the elderly.
• Cognitive behavioral therapy is the primary treatment, but pharmacotherapy is often necessary when it is insufficient.
• Traditional insomnia medications include benzodiazepines and nonbenzodiazepine GABA-A receptor agonists.

Purpose of the Study:

• To review current and emerging pharmacotherapeutic options for treating chronic insomnia.
• To discuss the role of newer agents like orexin inhibitors in insomnia management.
• To provide an overview of available medications for overcoming sleep barriers.

Main Methods:

• Literature review of pharmacotherapeutic agents for insomnia.
• Analysis of approved and investigational insomnia medications.
• Discussion of medication classes including traditional and novel agents.

Main Results:

• Suvorexant and lemborexant are currently approved orexin inhibitors for insomnia.
• Orexin inhibitors may offer improved safety profiles, including reduced dependence potential.
• Several other orexin receptor antagonists are in late-stage development.

Conclusions:

• Pharmacotherapy plays a crucial role in managing chronic insomnia when behavioral therapies are insufficient.
• Orexin inhibitors represent a significant advancement in insomnia pharmacotherapeutics.
• The landscape of insomnia treatment is evolving with new agents offering potentially better efficacy and safety profiles.